BioArctic receives positive opinion for Orphan Medicinal Product Designation in the EU for exidavnemab in Multiple System Atrophy

Stockholm, May 22, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that The European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) recommends granting orphan medicinal product designation to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need.

The release as fetched from its publisher. bioarctic.com ↗